Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
Open accessPublished version of a preprint
The DOI matches its Crossref record; 331 of the 348 references it cites were found in a registry or an index; 216 of the 381 sources its claims cite were checked for support.
Abstract
The American Diabetes Association and the European Association for the Study of Diabetes convened a panel to update the previous consensus statements on the management of hyperglycemia in type 2 diabetes in adults, published since 2006 and last updated in 2019. The target audience is the full spectrum of the professional health care team providing diabetes care in the U.S. and Europe. A systematic examination of publications since 2018 informed new recommendations. These include additional focus on social determinants of health, the health care system, and physical activity behaviors, including sleep. There is a greater emphasis on weight management as part of the holistic approach to diabetes management. The results of cardiovascular and kidney outcomes trials involving sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide 1 receptor agonists, including assessment of subgroups, inform broader recommendations for cardiorenal protection in people with diabetes at high risk of cardiorenal disease. After a summary listing of consensus recommendations, practical tips for implementation are provided.
Overview
CoChat Summary
TL;DR
This 2022 ADA/EASD consensus report updates person-centered management of hyperglycemia in nonpregnant adults with type 2 diabetes, emphasizing holistic care, weight management, physical activity, DSMES, and individualized medication selection. It gives strongest priority to GLP-1 receptor agonists and SGLT2 inhibitors for people with established or high-risk cardiovascular, kidney, or heart failure disease, based on evidence synthesized from trials and meta-analyses published through 13 June 2022.
Key findings
- A PubMed search identified randomized controlled trials, systematic reviews, and meta-analyses published in English between 28 January 2018 and 13 June 2022; the report built on the 2012, 2015, 2018, and 2019 consensus statements.
- In a network meta-analysis of 453 trials across nine drug classes, the greatest HbA1c reductions were seen with insulin regimens and GLP-1 RA; subcutaneous semaglutide had the greatest body-weight reduction, and SGLT2i and GLP-1 RA had the greatest blood-pressure reductions.
- In comparative effectiveness analyses, SGLT2i were superior to GLP-1 RA for reducing heart failure hospitalization and a composite kidney outcome, while GLP-1 RA appeared more efficacious for stroke; no important differences were evident for mortality or other cardiovascular outcomes.
- The report states that DSMES significantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective; it also reports specific trial effects such as STEP 2 weight loss of 9.6% with semaglutide 2.4 mg, and AWARD-11 and SUSTAIN FORTE showing greater HbA1c and weight reductions with higher-dose GLP-1 RA.
Methods
- Consensus report written by an ADA/EASD panel, using prior consensus reports as the starting point and incorporating evidence from publications since 2018.
- Evidence source: PubMed search for English-language RCTs, systematic reviews, and meta-analyses published between 28 January 2018 and 13 June 2022, plus reference-list screening for additional studies.
- Evidence appraisal: papers were grouped by topic, subgroup meta-analyses were assessed for credibility using relevant guidance, and recommendations were informed by GRADE; draft recommendations were reviewed by invited reviewers and opened for public comment.
Limitations
- The paper states that subgroup analyses should not be regarded as conclusive and should be formally appraised and ideally complemented by relevant RCTs.
- The text notes that evidence is limited for some populations because of underrepresentation in trials, including younger people, older adults, women, and non-White participants; this is an evident limitation of generalizability.
- The report also makes evident that some conclusions rely on network meta-analyses, observational data, and nonrandomized studies, and that some outcomes (e.g., long-term cardiovascular profile of tirzepatide) were still pending, which limits certainty.
Model-written summary of a shortened version of the paper’s full text (it is longer than we read). Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
140 Valid · 9 Not valid · 61 Not checked · 27 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Some inferences about the effect of glucose-lowering medications as primary cardiovascular prevention in populations with low cardiovascular risk can be made from network meta-analyses, suggesting that no agent or drug class has a notable bene fi cial effect on cardiovascular events in lowrisk individuals with diabetes (223,259).”
What the sources say
- Not checked — no full text of the sourcecites [223] Tsapas, 2020, Comparative effectiveness of glucose-lowering drugs for type 2 diabetes: a systematic review and network meta-analysis, Ann Intern Med source
- Disputedcites [259] Palmer, 2021, Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials, BMJ sourceExperimental — accuracy not yet measured
The Results > Outcomes section reports fewer non-fatal myocardial infarctions with both drug classes in low-risk patients and fewer non-fatal strokes with GLP-1 receptor agonists. That contradicts the claim that no drug class benefits cardiovascular events in this group. The Discussion > Clinical uncertainties section cautions that trials generally did not include the lowest-risk patients and does not judge whether the absolute effects are clinically notable. (LLM, conf=0.85)
Checked by a reasoning model — may be wrong.
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“As with any laboratory test, HbA1c measurement has limitations (2,52).”
What the sources say
- Supportedcites [2] Draznin, 2022, 6. Glycemic targets: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The “A1C Limitations” section (p. 2) explicitly says the A1C test is subject to limitations and that its measurement varies, as with any laboratory test. (LLM, conf=0.95)
- Supportedcites [52] American Diabetes Association Professional Practice Committee, 2022, 2. Classification and diagnosis of diabetes: Standards of Medical Care in Diabetes—2022, Diabetes Care source
The Fasting and 2-Hour Plasma Glucose section explicitly refers to “these limitations with A1C,” including lower diagnostic sensitivity and imperfect correlation with average glucose in some individuals. The Race/Ethnicity/Hemoglobinopathies section also notes that hemoglobin variants can interfere with A1C measurement. (LLM, conf=0.94)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Thus, these multifaceted domains (heterogeneity across individual characteristics, social determinants of health, and psychosocial factors) challenge individuals with diabetes, their families, and their providers when attempting to integrate diabetes care into daily life (49).”
What the sources say
- Supportedcites [49] Young-Hyman, 2016, Psychosocial care for people with diabetes: a position statement of the American Diabetes Association, Diabetes Care source
The Introduction says complex environmental, social, behavioral, and emotional factors challenge people with diabetes and their families as they integrate care into daily life. Life Course Considerations identifies social determinants and person-based characteristics as factors providers should consider, while the Conclusions describes challenges to providing that care. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Type 2 diabetes is a very heterogeneous disease with variable age at onset, related degree of obesity, insulin resistance, and tendency to develop complications (39,40).”
What the sources say
- Supportedcites [39] Ahlqvist, 2018, Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables, Lancet Diabetes Endocrinol source
The Abstract describes type 2 diabetes as highly heterogeneous and identifies age at diagnosis, BMI, and insulin resistance as clustering variables. It reports that the resulting clusters differed in patient characteristics and risk of complications, supporting the claimed variation. (LLM, conf=0.92)
- Supportedcites [40] Pigeyre, 2022, Validation of the classification for type 2 diabetes into five subgroups: a report from the ORIGIN trial, Diabetologia source
The Introduction describes heterogeneity in diabetes presentation and progression. The Results identify subgroups differing in age at diagnosis, BMI and insulin-resistance-related characteristics; the Abstract reports differences in renal outcomes between subgroups. Together, these passages support the cited statement about variation among people with type 2 diabetes. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“High-quality evidence has consistently shown that DSMES signi fi cantly improves knowledge, glycemic levels, and clinical and psychological outcomes, reduces hospital admissions and all-cause mortality, and is cost-effective (22,25 -30).”
What the sources say
- Not checked — no full text of the sourcecites [22] Draznin, 2022, 5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes–2022, Diabetes Care source
- Partly supportedcites [25] Chrvala, 2016, Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control, Patient Educ Couns sourceExperimental — accuracy not yet measured
The Introduction says evidence from randomized and observational studies suggests DSME is cost-effective. The citing sentence presents cost-effectiveness as a consistently demonstrated finding, whereas this review does not establish it; Practical implications says DSME must be cost-effective, not that the review found it to be so. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [26] Pillay, 2015, Behavioral programs for type 2 diabetes mellitus: a systematic review and network meta-analysis, Ann Intern Med source
- Not checked — no full text of the sourcecites [27] Zhao, 2017, Theory-based self-management educational interventions on patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials, J Adv Nurs source
- Partly supportedcites [28] Odgers-Jewell, 2017, Effectiveness of group-based self-management education for individuals with type 2 diabetes: a systematic review with meta-analyses and meta-regression, Diabet Med sourceExperimental — accuracy not yet measured
The Introduction (page not supplied) says group-based education for people with type 2 diabetes may be more cost-effective than individual education because it requires less time and funding. That qualified comparison does not establish the broader, unqualified claim that DSMES is cost-effective. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [29] He, 2017, Diabetes self-management education reduces risk of all-cause mortality in type 2 diabetes patients: a systematic review and meta-analysis, Endocrine source
- Not checked — no full text of the sourcecites [30] Chatterjee, 2018, Diabetes structured self-management education programmes: a narrative review and current innovations, Lancet Diabetes Endocrinol source
boosted- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
127 more claims · 71 with their cited sources checked
Create a free account to see all 237 claims and every source verdict.
- It may state two separate claims as one. 88
- Probably not a substantial claim. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The DiRECT dietary intervention was highly costeffective and deliverable in primary care. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“thus cost-savings might be greater. 11”
From 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study (2024) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In people with T2D and established cardiovascular disease, the international guidelines for T2D recommend the use of GLP-1 RA or sodium glucose co-transporters 2 inhibitors (SGLT-2i) as first-line treatment (independent of HbA1c), based on multiple trials demonstrating their cardio-renal benefits [109].”
From What is the pipeline for future medications for obesity? (2025) · cites this paper as [109]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This may be particularly important in young-onset T2D where higher rates of obesity, more rapid deterioration in blood glucose levels and earlier development of diabetes complications have been observed [9,95].”
From Oral glucagon-like peptide-1 receptor agonists and combinations of entero-pancreatic hormones as treatments for adults with type 2 diabetes: where are we now? (2024) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Increase insulin secretion regardless of glycemia, typically resulting in 2–3 kg weight gain [44].”
From Precision obesity medicine: A phenotype-guided framework for pharmacologic therapy across the lifespan (2025) · cites this paper as [44]
Experimental — accuracy not yet measured
25 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
World Health Organization 2020 guidelines on physical activity and sedentary behaviour
Bull, F. C., Al-Ansari, S. S., Biddle, S., Borodulin, K., Buman, M. P., Cardon, G., Carty, C., Chaput, J.-P., Chastin, S., Chou, R., et al. (2020) · British Journal of Sports Medicine · doi:10.1136/bjsports-2020-102955 · Cited by 11,657
Sun, H., Saeedi, P., Karuranga, S., Pinkepank, M., Ogurtsova, K., Duncan, B. B., Stein, C., Basit, A., Chan, J. C. N., Mbanya, J. C., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.109119 · Cited by 10,123
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Decision aids for people facing health treatment or screening decisions
Stacey, D., Légaré, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B., Holmes-Rovner, M., Llewellyn-Thomas, H., Lyddiatt, A., Thomson, R., et al. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001431.pub5 · Cited by 6,685
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189 · cited 20×
“Notably, the benefits of GLP-1 RA and SGLT2i for cardiovascular and renal outcomes have been found to be independent of metformin use, and thus these agents should be considered in people with established or high risk of CVD, HF, or CKD, independent of metformin use (173–175).”
BackgroundInfluential
Research works printed but not linked: 2
- Nathan, Glycemic outcomes in the glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study, N Engl J Med
- Nathan, Glycemia reduction approaches in type 2 diabetes: a comparative effectiveness (GRADE) study microvascular and cardiovascular outcomes, N Engl J Med
Cited by
Items 801–900 of 2,053
Ortega, E., Redondo‐Antón, J., Díaz‐Cerezo, S., Santos, M. R., & Romera, I. (2025) · Advances in Therapy · doi:10.1007/s12325-025-03230-7 · Cited by 6
“Guidelines from the American Diabetes Associa‑ tion (ADA) and the European Association for the Study of Diabetes (EASD) recommend a holis‑ tic person‑centred approach to type 2 diabetes (T2D) management, with goals of care being to prevent complications while optimising quality of life [1].”
InfluentialKatz, G. (2025) · Hormone and Metabolic Research · doi:10.1055/a-2569-7315 · Cited by 7
Lane, J., & Fontaine, K. R. (2021) · OBM Integrative and Complementary Medicine · doi:10.21926/obm.icm.2102015 · Cited by 5
Metformin and Infections: What Is the Next Step in This Decades-Long Story?
Goto, M., & Perencevich, E. N. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac903 · Cited by 4
Thewjitcharoen, Y., Yenseung, N., Butadej, S., Nakasatien, S., Chotwanvirat, P., Chatchomchuan, W., Wanothayaroj, E., Krittiyawong, S., & Himathongkam, T. (2023) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.038.01.11 · Cited by 5
Potential of nutrition in body weight improvement in type 2 diabetes
Олеговна, Е. С., & Drapkina, O. M. (2023) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2023-3607 · Cited by 5
Aroda, V. R., & Billings, L. K. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.06.005 · Cited by 4
Self-citationDietary Patterns and Physical Activity Levels Among People With Type 2 Diabetes
Rashid, T., Afnan, B. H., Baloch, A. A., Mughal, S., Hasan, M. J., & Khan, M. U. (2023) · Nutrition and Metabolic Insights · doi:10.1177/11786388231189591 · Cited by 11
Glucocentric and cardiocentric approaches to achieving type 2 diabetes compensation
Pankiv, V. І. (2023) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.19.5.2023.1297 · Cited by 4
Mediterranean diet, type 2 diabetes prevention and healthy ageing: Do we need more evidence?
Maltese, G., Koufakis, T., Kotsa, K., Basile, G., & Siow, R. C. M. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110928 · Cited by 6
Aberle, J., Lautenbach, A., Meyhöfer, S., Meyhöfer, S. M., Menzen, M., Selig, L., Mai, K., & Blüher, M. (2023) · Diabetologie und Stoffwechsel · doi:10.1055/a-2076-0105 · Cited by 6
“Der Konsensus Bericht der „ American Diabetes Association “ (ADA) und der „ European Association for the Study of Diabetes “ (EASD) von 2022 [7] definieren für die meisten Menschen mit Typ 2 Diabetes eine Gewichtsreduktion von mindestens 5 – 15 % als Therapieziel, wobei eine 10 – 15%ige Abnahme…”
Mustač, F., Galijašević, T., Podolski, E., Belančić, A., Matovinović, M., & Marčinko, D. (2023) · Diabetology · doi:10.3390/diabetology4040041 · Cited by 5
Cuenca, A. M. C., Moreno-Pérez, O., Campuzano-Ruiz, R., Soler, M. J., de Lucas, M. D. G., & Orozco‐Beltrán, D. (2023) · Archives of Medical Research · doi:10.1016/j.arcmed.2023.102923 · Cited by 5
Hironaka, J., Okada, H., Minamida, M., Kondo, Y., Nakajima, H., Majima, S., Kitagawa, N., Okamura, T., Senmaru, T., Ushigome, E., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15487 · Cited by 4
“33 The European Association for the Study of Diabetes also supports a person-centred approach to glycaemic management.”
BackgroundErukulapati, R. S., Manikandan, R. M., Jakkidi, L. R., Sathyanarayana, S. O., Ayyagari, U., Aswathiah, S., Nalla, S., Sampath, S. K., Manohar, S. P., Shah, S. C., et al. (2024) · Clinical Diabetology · doi:10.5603/cd.98136 · Cited by 7
“Educating to self-titrate insulin doses based on blood glucose monitoring (BGM) improves glycemic control in people with T2D who are initiated on insulin [13].”
BackgroundGraue, M., Igland, J., Oftedal, B. F., Haugstvedt, A., Riise, H. K. R., Zoffmann, V., Jenum, A. K., Richards, D. A., & Kolltveit, B. H. (2024) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2024.2337071 · Cited by 5
“…and prevent or delay the development of diabetes at an early stage might best be maintained when people are supported by an interprofessional team [9]. the evidence on integrated care approaches in specialist healthcare is well understood; however, role construction and boundaries within primary…”
BackgroundMalik, R. A., Hwu, C., Jammah, A. A., Arteaga-Díaz, J. M., Djaballah, K., Pilorget, V., Alvarez, A., Vera, C., & Vikulova, O. K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15599 · Cited by 7
Aung, N. L. (2024) · Clinical Diabetes · doi:10.2337/cd24-0038 · Cited by 5
Semaglutide in Cardiometabolic Diseases: SELECTing the Target Population
Natale, F., Luisi, E., Franzese, R., Mollo, N., Solimene, A., Caso, V. M., Corvino, A., Golino, P., & Cimmino, G. (2024) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd11050145 · Cited by 8
“If indicated, early-stage, single or combination therapy with oral glucose-lowering agents is recommended until injectable therapy with more effective drugs (insulin or GLP-1 receptor agonists) becomes necessary [4,69].”
BackgroundInfluentialHu, S., Shi, C., Ma, Y., Wang, S., Gu, S., Qi, C., & Fan, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15645 · Cited by 4
Posma, R. A., Bakker, S. J. L., Nijsten, M. W., Touw, D. J., & Tsikas, D. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133692 · Cited by 4
“Metformin ( N , N -dimethylbiguanide) is the most commonly prescribed oral antihyper-glycemic drug to treat type 2 diabetes [1].”
BackgroundLiberty, I. A., Septadina, I. S., Mariana, M., Novita, E., Amalia, R., Ananingsih, E. S., Hasyim, H., & Hanifah, L. (2024) · PLoS ONE · doi:10.1371/journal.pone.0305604 · Cited by 6
“At the same time, in many countries including Indonesia, economic growth and social changes have triggered shifts in dietary intake and physical activity at the population level, resulting in a significant increase in diabetes prevalence [10].”
BackgroundAdamson, K., Gibb, F. W., McLaren, J. B., Min, T., Price, H. C., Sankaranarayanan, S., & Strzelecka, A. (2024) · Diabetes Therapy · doi:10.1007/s13300-024-01629-z · Cited by 5
Yamada, Y., Yabe, D., Shide, K., et al. (2024) · Journal of Diabetes Investigation · doi:10.1111/jdi.14287 · Cited by 4
Марущак, М. І., Гевко, У. П., Krynytska, І., Danylevych, Y. O., Danchak, S. V., & Mazur, L. (2021) · Archives of the Balkan Medical Union · doi:10.31688/abmu.2021.56.1.03 · Cited by 4
Trialing precision medicine for type 2 diabetes
Pilla, S. J., Mathioudakis, N. N., & Maruthur, N. M. (2023) · Nature Medicine · doi:10.1038/s41591-022-02168-5 · Cited by 6
Self-citationDoes Metformin Assist New Anti-Diabetic Drugs to Succeed?
Kastuyama, H., & Yanai, H. (2019) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3706 · Cited by 4
Araldi, E., Jutzeler, C. R., & Ristow, M. (2023) · medRxiv · doi:10.1101/2023.05.19.23290214 · Cited by 4
Inceu, G. V., Crăciun, A.-E., Ciobanu, D. M., Berchisan, A., Fodor, A., Bala, C., Roman, G., & Rusu, A. (2025) · Medicina · doi:10.3390/medicina61081343 · Cited by 3
“…the efficacy in reducing HbA1c, accompanied by a weight loss effect, low risk of hypoglycemia, and ease of use (simple titration plan and once-daily or even once-weekly administration), the ADA/EASD Guideline recommends to preferentially use GLP-1 RAs in T2D patients before insulin therapy [3,4].”
Magalhães, J. P., Oliveira, E. C., Hetherington‐Rauth, M., Jesus, F., Rodrigues, M. C. D. F. S., Raposo, J. F., Ribeiro, R. T., Caetano, C. G., & Sardinha, L. B. (2024) · Trials · doi:10.1186/s13063-024-08335-y · Cited by 5
Zhang, W., Zhu, X., Que, X., & Zhang, X. (2024) · Digital Health · doi:10.1177/20552076241272514 · Cited by 11
“7 Older adults with T2DM face tougher challenges.”
BackgroundCai, Y., Liu, F.-H., Sun, J., & Lin, C. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.11.016 · Cited by 4
Arietti, P., Boye, K. S., Guidi, M., Rachman, J., Federici, M. O., Raiola, R., Avitabile, A., & Valentine, W. J. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-024-01553-w · Cited by 3
“It is well established that controlling modifiable risk factors, such as blood glucose levels and body weight, can reduce the risk of both micro-and macrovascular complications in patients with type 2 diabetes [8].”
Influentialda Silva, F. L. D. M. R., Fernandes, A. C., Kraemer, M. V. D. S., Padovan, M., Bernardo, G. L., Uggioni, P. L., Rafacho, A., & Proença, R. P. D. C. (2025) · Nutrients · doi:10.3390/nu17061061 · Cited by 5
“…in guidelines by Ramos et al. [8], Diabetes UK [86], Diabetes Canada [87], Diabetes Australia [88], and ADA [89]; the consensus of associations by Davies et al., [90]; and expert consensus by Evert et al. [4] are compiled in Table 3 and described in detail in Table S2 (Supplementary Material).”
Wilmot, E. G., Ajjan, R., Cheah, Y. S., Choudhary, P., CRANSTON, I. C., Elliott, R. A., Evans, M. L., Iqbal, A., Kamaruddin, S., Barnard-Kelly, K. D., et al. (2025) · BMJ Open · doi:10.1136/bmjopen-2024-090154 · Cited by 6
Παπάνας, Ν., Tsimihodimos, V., Katsiki, N., Doupis, J., Pagkalos, E. M., Nikas, N., Papakonstantopoulos, N., Karpouzos, G., & Tentolouris, N. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.109087 · Cited by 4
Registered clinical trials targeting type 2 diabetes remission with pharmacological interventions
Shoung, N., Carette, C., Rassy, N., Phan, A., Greenfield, J. R., Hu, F. B., Rives‐Lange, C., & Czernichow, S. (2025) · Scientific Reports · doi:10.1038/s41598-025-00080-9 · Cited by 5
Safety and Effectiveness of Tirzepatide in Solid-Organ Transplant Recipients
Sweiss, H., Flores, R., Windler, S., Hall, R., Bhayana, S., Patel, R., & Long, C. M. (2025) · Diabetes Spectrum · doi:10.2337/ds24-0071 · Cited by 5
Vujosevic, S., Toma, C., Ferrulli, A., Cillà, S. D., Nucci, P., & Luzi, L. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02552-w · Cited by 6
The Evolving Role of GLP-1 Receptor Agonists in MASLD: Current Evidence and Future Directions
Zasadzińska, M., Borowski, G., Bakuła, P. R., & Jałocha, K. (2025) · Journal of Diabetology · doi:10.4103/jod.jod_18_25 · Cited by 4
Halimi, J., Fauchier, L., Karras, A., Amouyal, C., Eladari, D., Rossignol, P., Choukroun, G. J., Zaoui, P., Girerd, N., & Hadjadj, S. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf426 · Cited by 9
Savitri, M., Tallei, T. E., Adam, A. A., Maulydia, N. B., Fatimawali, F., Tanjung, G. S., Firdaus, M. D. K., Syahputra, R. A., & Nurkolis, F. (2025) · Food Bioscience · doi:10.1016/j.fbio.2025.107371 · Cited by 4
Liu, Y., Li, H., Zhao, Q., & Cui, W. (2025) · Nutrition & Metabolism · doi:10.1186/s12986-025-00968-3 · Cited by 191
“…analysis and based on both nutritional content and delivery modality, in alignment with national and international dietary guidelines for T2DM (e.g., ADA 2022 [8]; Chinese Nutrition Society 2022 [6]; Hou et al. 2023 [19]; Iizuka and Yabe 2023 [25]; Nolan et al. 2022 [41]; Chinese et al. 2024 [5]).”
Nanocarrier-based insulin delivery: A leap towards a needle-free future
Balasubramaniyam, S., Rathinam, T., Srinivasan, M., & Jayarani, S. (2025) · Nano TransMed · doi:10.1016/j.ntm.2025.100093 · Cited by 6
Bharaj, I. S., Purewal, K., Munaim, J., Brar, A. S., Kacheria, A., Simister, A., Thirupathy, U., Gupta, P., Kahlon, J., Thwe, E. E., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13092192 · Cited by 7
“In fact, clinical guidelines highlight the substantial cardiovascular benefits of GLP-1Ras, demonstrating a robust capacity to reduce MACE and all-cause mortality, making them a key consideration in managing this vulnerable population [38,40].”
New therapeutic agents for type 2 diabetes: anaesthetic considerations. A narrative review
Doroba, O., Czupryniak, L., Sanfilippo, F., Andruszkiewicz, P., & Zawadka, M. (2025) · Anaesthesiology Intensive Therapy · doi:10.5114/ait/208895 · Cited by 6
“How ever, in patients with established atherosclerotic cardiovascular disease, high cardiovascular risk, or chronic kidney disease, they are now recommended as firstline therapy [22].”
Risk management of cardiovascular disease in older patients with diabetes
Sawami, K., Tanaka, A., & Node, K. (2025) · Hypertension Research · doi:10.1038/s41440-025-02424-4 · Cited by 4
“GLP-1RA are less likely to cause hypoglycemia when used alone, while having a higher glucose-lowering effect [14].”
Kassem, S., Khalaila, B., Stein, N., & Zaina, A. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i11.112999 · Cited by 4
The adipokine Isthmin-1 in obesity and its complications: recent research advances
Zhuang, Y., Liu, J., Sui, Y., Song, J., Yuan, G., & Zhao, L. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.124092 · Cited by 4
Ali, H. I., Harbi, A. I. A., Alnahdi, M., Alshamsi, M. S., Aldhaheri, M. R., Meqbaali, S. M. A., Aldahmani, M. A., Ilesanmi-Oyelere, B. L., Dhaheri, A. S. A., Ismail, L. C., et al. (2025) · Journal of Primary Care & Community Health · doi:10.1177/21501319251388306 · Cited by 4
“53 On the other hand, the combination of exercise, healthy eating, and proper sleep mentioned by some participants in the present study aligns with established guidelines for diabetes self-management, 54 emphasizing a holistic approach to managing diabetes.”
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2025) · Diabetologie und Stoffwechsel · doi:10.1055/a-2592-9700 · Cited by 7
Jamal, A., Khan, S., Qadri, M., Shah, A., Iftikhar, H., Fatima, E., Ahmad, M., Sikandar, M., Jawed, I., Muneeb, M., et al. (2026) · Acta Diabetologica · doi:10.1007/s00592-025-02635-8 · Cited by 3
Prescription Patterns of Sodium-Glucose Co-Transporter 2 Inhibitors among Nephrologists
Gopal, A., Nair, R. R., Kurian, G., Mathew, A., Polachirakal, Z. P., & Seetha Lakshmy, K. D. (2026) · Indian Journal of Nephrology · doi:10.25259/ijn_784_2025 · Cited by 3
RSSDI guidelines for management of type 2 diabetes mellitus in older adults
Jagadeesha, A., Viswanathan, V., Agarwal, S., Maheshwari, A., Virmani, A. K., Nagendra, L., Amarnath, A., Chawla, M. S., Jethwani, P., Parikh, R. M., et al. (2026) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-025-01613-8 · Cited by 4
GLP-1 Receptor Agonists at the Crossroads of Circadian Biology, Sleep, and Metabolic Disease
Gandhi, A., Phyu, E. M., Koom‐Dadzie, K., Dickson, K. B., & Halm, J. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27062853 · Cited by 6
“When symptoms arise, it is reasonable to assess whether they cluster around dosing time and consider timing adjustments alongside standard mitigation strategies such as slower up-titration, smaller meals, avoidance of high-fat foods, and adequate hydration [112,113].”
Giorgino, F., DʼSOUZA, S., Ludwig, L., Kiyosue, A., Ibriga, H., RHA, H., Denning, M., Wu, W.-S., Landó, L. F., & Tobian, J. A. (2026) · JAMA · doi:10.1001/jama.2026.9512 · Cited by 8
Metabolic Modulation in Cancer Care: The Potential Role of Glucagon-Like Peptide-1 Receptor Agonists
Temperley, H. C., & Kelly, M. E. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-26-00062 · Cited by 3
“54”
Mohamed, D. A.-W., Elayat, W. M., Zeid, A. A. A., Abdel-Salam, M. F., Teama, N. M., Abdelrahim, D. S., & Tamim, Y. M. (2021) · Journal of Endocrinology and Metabolism · doi:10.14740/jem765 · Cited by 3
Hassaan, M., Elsayed, A. M. E., Deraz, H. A., et al. (2022) · The Egyptian Journal of Hospital Medicine · doi:10.21608/ejhm.2022.266047 · Cited by 3
Diabetes Management and Outcomes among Patients with Type 2 Diabetes Attending a Renal Service
Skalkos, E., Rajagopal, R., & Simmons, D. S. (2023) · Journal of Diabetes Research · doi:10.1155/2023/1969145 · Cited by 5
“Achievement of metabolic targets, as defined by RACGP guidelines, reduces the risk or slows the progression of CKD in T2DM [6, 9, 10].”
BackgroundKıraç, C. O., Şirikçi, V., & Fındıklı, H. A. (2023) · Medicine · doi:10.1097/md.0000000000034696 · Cited by 5
“[5,6] Many oral antidiabetic agents and injectable treatment options are available to achieve glycemic control.”
BackgroundLiébana, L. R. (2023) · Diabetes práctica · doi:10.52102/diabet/pract.2023.3.art3 · Cited by 5
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2024) · Diabetologie und Stoffwechsel · doi:10.1055/a-2251-2772 · Cited by 3
Open questions on basal insulin therapy in T2D: a Delphi consensus
Delphi Board, Alberto, A., Roberto, A., Angelo, A., Baggiore, C., cesare, B., Bonadonna, R. C., Giuseppe, C. S. M., Andrea, D. P., Lorenzo, D. C., et al. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02285-2 · Cited by 3
“In particular, the consensus report by ADA and EASD recommend GLP-1 RA as first injectable medication for patients with atherosclerotic cardiovascular disease or indicators of high risk [2].”
BackgroundInfluentialHenry, Z., Villar, E., Chauvet, C., Belloi, A., Prunescu, I., Doroszewski, F., Luyton, C., & Marchand, L. (2024) · Acta Diabetologica · doi:10.1007/s00592-024-02323-z · Cited by 4
Bartoszko, J. M., & van Klei, W. A. (2024) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-024-02809-y · Cited by 3
“12,13 Semaglutide has approval from the U. S. Food and Drug Administration as a weight loss drug in patients with and without diabetes mellitus.”
Alluhidan, M., Alturaiki, A., Alabdulkarim, H. A., Aljehani, N., Alghamdi, E. A., Alsabaan, F., Alamri, A. A., Malkin, S. J. P., Hunt, B., Alhossan, A., et al. (2024) · Advances in Therapy · doi:10.1007/s12325-024-02978-8 · Cited by 4
“Published treatment guidelines therefore often focus on controlling HbA1c as a key surrogate marker for people with type 2 diabetes [10, 11].”
InfluentialJouabadi, S. M., Peymani, P., Shahraki, M. N., van Rooij, J., Broer, L., Roks, A. J. M., Stricker, B. H. C., & Ahmadizar, F. (2024) · The Pharmacogenomics Journal · doi:10.1038/s41397-024-00352-z · Cited by 6
“Metformin is a biguanide Oral Glucose-Lowering Medication (OGLM), approved as a fi rst-line pharmacotherapy for type 2 diabetes mellitus (T2DM) worldwide [1].”
Karagiannakis, D. S., Stefanaki, K., Paschou, S. Α., Papatheodoridi, Μ., Tsiodras, S., & Παπάνας, Ν. (2024) · HORMONES · doi:10.1007/s42000-024-00625-z · Cited by 5
Snel, T., Krone, T., Kamstra, R. J. M., Eggink, H. M., Pijl, H., de Graaf, A. A., & de Hoogh, I. M. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2024-004506 · Cited by 3
Ng, P. Y., Ng, A. K., Ip, A., Sin, W. C., & Yiu, K. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.124.037207 · Cited by 3
Gautier, S., Truong-Minh, J., Béné, J., Temime, J., Granier, M., Hennart, B., Bergeron, S., & Jaillette, E. (2024) · Therapies · doi:10.1016/j.therap.2024.12.009 · Cited by 3
Glucagon-like peptide-1 and impaired counterregulatory responses to hypoglycemia in type 1 diabetes
Rocha, G. R., & de Melo, F. F. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.99928 · Cited by 4
Takyi, A. K., Gaffey, R. H., & Shukla, A. P. (2025) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-024-00465-1 · Cited by 4
“…the Study of Diabetes (EASD), findings from large cardiovascular outcome trials (CVOTs) also have not indicated an elevated risk of pancreatitis or pancreatic cancer associated with GLP-1 receptor agonists but discontinuation of treatment is recommended if pancreatitis is suspected [65, 67, 68].”
Mahmoud, M. R., Ibrahim, S., Shahien, M. M., Alshammari, A. D., Alenazi, F., Alreshidi, F. S., Aljadani, A., Khalik, A. A., Elhaj, A. H., Khalifa, A. M., et al. (2025) · Healthcare · doi:10.3390/healthcare13040376 · Cited by 5
Müssig, K., Gallwitz, B., Haak, T., Kellerer, M., & Siegel, E. G. (2025) · Diabetes aktuell · doi:10.1055/a-2500-1766 · Cited by 5
Singh, N., Singh, A. K., Patni, B., Agarwal, P., Nageshappa, M. K., Prasad, M. K., Chhabra, M., Singha, N. G., Shunmugavelu, M., Gupta, A., et al. (2025) · Journal of the Association of Physicians of India · doi:10.59556/japi.73.0887 · Cited by 4
“…for T2D should align with the guidelines provided by the American Diabetes Association (ADA), the European Association for the Study of Diabetes (EASD), 25 29 ; **According to the ADA and Food and Drug Administration (FDA) guidelines, SGLT2i should be discontinued 3 days before scheduled surgeries.”
Nørlev, J. T. D., Kronborg, T., Jensen, M. H., Rana, P., Vestergaard, P., & Hangaard, S. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112191 · Cited by 4
Barrea, L., Caprio, M., Perrini, S., Camajani, E., Crafa, A., Gangitano, E., Gorini, S., Sciacca, L., Verde, L., Albertelli, M., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02589-2 · Cited by 5
“SGLT2 inhibitors are oral anti-diabetes medications that reduce plasma glucose by enhancing urinary excretion of glucose [ 161 ].”
InfluentialCharles, M., Schousboe, K., Thybo, T., Hall-Andersen, E. K., & Knudsen, S. T. (2025) · Primary care diabetes · doi:10.1016/j.pcd.2025.05.002 · Cited by 3
Special considerations in assisted reproductive technology for patients with obesity
Johnson, A., Vu, T.-G. T., Simon, J., & Ryan, G. L. (2025) · Fertility and Sterility · doi:10.1016/j.fertnstert.2025.04.050 · Cited by 4
Han, Y.-N., Li, S.-P., Wang, Y., Xiao, Z.-X., & Li, C. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1597521 · Cited by 4
Talyshinskii, A., Nedbal, C., & Somani, B. K. (2025) · Current Opinion in Urology · doi:10.1097/mou.0000000000001306 · Cited by 5
Ha, K. H., Park, M., Lee, Y., Kim, D. J., & Han, S. J. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101668 · Cited by 3
af Hagelsrum, K. D., Andermo, S., Svedberg, T., Rosen, P., Johansson, U., Hagströmer, M., & Rossen, J. (2025) · BMC Digital Health · doi:10.1186/s44247-025-00154-8 · Cited by 3
Adverse Drug Reactions to SGLT2i Reported by Type 2 Diabetes New Users: An Active Surveillance Study
Bucșa, C., Frenț, I., Ştefan, R., Fodor, A., Inceu, G., Farcas, A. M., Rusu, A., Negovan, M., & Mogoșan, C. (2025) · Pharmaceuticals · doi:10.3390/ph18060904 · Cited by 5
“Current T2D guidelines recommend SGLT2i use for cardiorenal risk reduction in high-risk patients with T2D [13].”
Štuhec, M., Svetanic, N., Vovk, T., Gazdag, A. G., Cuk, Z., & Batinić, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1667584 · Cited by 8
Chow, J., Lim, W., Li, L., Yu, Q., Zhong, Y., Wang, Z., Shah, S. A. A., Zhu, C., Yan, S., Liu, H., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02655-9 · Cited by 4
“DPP-4i enhance GSIS and suppress glucagon release by inhibiting the degradation of incretin hormones, primarily glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) [ 10 ].”
Benouchenne, D., Djeghim, H., Benslama, O., Alsaeedi, H., Cornu, D., Bechelany, M., & Barhoum, A. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1592468 · Cited by 4
Consenso ALAD. Tratamiento del paciente con diabetes mellitus tipo 2 y obesidad
BRAJKOVICH, I. E., Aschner, P. J., Taboada, L. B., Camperos, P., Gómez‐Pérez, R., Aure, G., Velásquez, M. E., Halpern, B., Jiménez, M. C. H., & Fuentes, O. (2019) · Alad · doi:10.24875/alad.19000369 · Cited by 11
Is there an association between upper limb claudication and handgrip strength in Takayasu arteritis?
dos Santos, A. M., Missé, R. G., Borges, I. B. P., Pereira, R. M. R., & Shinjo, S. K. (2021) · Reumatismo · doi:10.4081/reumatismo.2020.1298 · Cited by 4
Zakaria, F., Ishak, W. R. W., Ahmad, W. A. N. W., et al. (2022) · Sains Malaysiana · doi:10.17576/jsm-2022-5103-12 · Cited by 3
Ferreira‐Hermosillo, A., & Elías-López, D. (2026) · Revista Mexicana de Endocrinología Metabolismo y Nutrición · doi:10.24875/rme.m21000013 · Cited by 7
Diabetes mellitus não controlada: inércia vs adesão à terapêutica
de Orta, U. G., Gonçalves, M. J., Fonseca, C. B., de Orta, U. G., Pintalhão, I., de Orta, U. G., Costa, R. V., de Orta, U. G., Henriques, M. O., de Orta, U. G., et al. (2023) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v39i1.13494 · Cited by 3
Empowering People with Diabetes: Role of Continuous Glucose Monitor Systems
Srivastava, S. B. (2023) · American Journal of Lifestyle Medicine · doi:10.1177/15598276231158044 · Cited by 5
“Other factors, including patient preferences, complexity of treatment regimen, and cost are important as well.(13,25) Lifestyle medicine interventions may lead to remission in people with certain health conditions including diabetes.”
BackgroundSaiti, A., Giannopoulos‐Dimitriou, A., Kazakos, I., Galatou, E., & Vizirianakis, I. S. (2023) · Future Pharmacology · doi:10.3390/futurepharmacol3010021 · Cited by 5
Seo, M. H. (2023) · Journal of Korean Diabetes · doi:10.4093/jkd.2023.24.1.5 · Cited by 4
Zdzierak, B., Zasada, W., Rakowski, T., et al. (2023) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.16502 · Cited by 3
Cribado de la retinopatía diabética mediante teleoftalmología en una zona básica de salud rural
Martín, Y. V., Gálvez, M. I. L., López-Herce, B. J., Hernández, A., & Contreras, M. G. R. (2023) · Atención Primaria · doi:10.1016/j.aprim.2023.102682 · Cited by 3
Metadata
- Authors
- Davies, M. J., Aroda, V. R., Collins, B. S., Gabbay, R. A., Green, J., Maruthur, N. M., Rosas, S. E., Del Prato, S., Mathieu, C., Mingrone, G., Rossing, P., Tankova, T., Tsapas, A., & Buse, J. B.
- Affiliations
- University of Leicester (GB)
- Brigham and Women's Hospital (US)
- National Heart, Lung, and Blood Institute (US)
- American Diabetes Association (US)
- Duke University (US)
- Johns Hopkins University (US)
- Joslin Diabetes Center (US)
- 9Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
- KU Leuven (BE)
- Università Cattolica del Sacro Cuore (IT)
- University of Copenhagen (DK)
- Medical University of Sofia (BG)
- 17Diabetes Centre, Clinical Research and Evidence-Based Medicine Unit, Aristotle University Thessaloniki, Thessaloniki, Greece
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Buse, John B.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2022-09-28
- Volume
- 45
- Issue
- 11
- Pages
- 2753-2786
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC10008140
- OpenAlex
- W4296802076
- Cited by
- 2,104
- References
- 348
- Citations by year
- 2026: 500 · 2025: 567 · 2024: 509 · 2023: 396 · 2022: 50
- FWCI
- 282.43
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (King's College London) (submittedVersion, other-oa)
- Lirias (KU Leuven) (submittedVersion)
- Funders
- European Association for the Study of Diabetes
- American Diabetes Association
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 2 diabetes, hyperglycemia management, glycemic targets, social determinants of health, physical activity, sleep, weight management, SGLT2 inhibitors, GLP-1 receptor agonists, cardiorenal protection, cardiovascular outcomes, renal outcomes
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Adult, Diabetes Mellitus, Type 2, Europe, Humans, Hyperglycemia, Hypoglycemic Agents, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-28, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-28 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.